Menu
Recruiting NCT06979141

Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression After General Anesthesia

Phase III Interventional Cough

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Dexmedetomidine, Magnesium sulfate, Lidocaine, normal saline.
Who it may be relevant to
Registry conditions: Cough. Basic parameters: 21 years — 60 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Comparative Study Between Efficacy of Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression During General Anesthetic Emergence

Overview

The aim of this prospective randomized controlled double-blinded study is to compare the efficacy of dexmedetomidine, MgSO4 and lidocaine for cough suppression during general anesthetic emergence as regard number and severity.

Interventions

  • Drug Dexmedetomidine
    Patients will receive 0.5 μg/kg dexmedetomidine in 10ml normal saline 10 min before the end of surgery.
  • Drug Magnesium sulfate
    Patients will receive 30 mg/kg IV magnesium sulfate 50% 10 min before the end of surgery.
  • Drug Lidocaine
    Patients will receive lidocaine 1.5 mg/kg lidocaine 10 min before the end of surgery.
  • Drug normal saline
    Patients will receive 10 ml normal saline 10 min before the end of surgery.

Primary outcome measures

  • Cough suppression as regard number and severity. [Time frame: at 0 and 10,20,30,40 minutes after endotracheal extubation.]
Secondary outcome measures (4)
  • Intraoperative heart rate (HR). [Time frame: at 15-minutes interval.]
  • Intraoperative mean arterial blood pressure (MAP). [Time frame: at 15-minutes interval.]
  • Intraoperative arterial oxygen saturation (Spo2). [Time frame: at 15-minutes interval.]
  • Sedation score. [Time frame: at 0,10,20,30, and 40 minutes after tracheal extubation.]

Eligibility criteria

Inclusion criteria

  • Aged 21-60 years.
  • Both genders.
  • Body mass index < 30 kg/ m2
  • American Society of Anesthesiology (ASA) physical status I-II.
  • Mallampati score class I or II.
  • Patients undergoing surgery under general anesthesia.

Exclusion criteria

  • Known allergy to study drugs.
  • History of psychiatric illness.
  • Patients with major organ diseases.
  • Pre-existing neurological deficits.
  • Body mass index >30 kg/m2.
  • Active airway infection or history of tracheal and laryngeal surgery.
  • Lower esophageal sphincter incompetence (and reflux).
  • Increased intracranial and intraocular pressure.
  • Use of cough-inducing medications
  • Pregnant, and lactating women.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Prevention

Study locations

Egypt · 1 center
  • Faculty of Medicine, Al-Azhar university Assiut, Egypt. — Asyut

Identifiers

NCT: NCT06979141 · MD/AZ.AST./AIP029/7/240/2/2025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗